Frontiers in Immunology (Nov 2021)
Persistence of High Levels of Serum Complement C5a in Severe COVID-19 Cases After Hospital Discharge
- Yaiza Senent,
- Yaiza Senent,
- Yaiza Senent,
- Susana Inogés,
- Susana Inogés,
- Susana Inogés,
- Ascensión López-Díaz de Cerio,
- Ascensión López-Díaz de Cerio,
- Ascensión López-Díaz de Cerio,
- Andres Blanco,
- Arantxa Campo,
- Francisco Carmona-Torre,
- Francisco Carmona-Torre,
- Francisco Carmona-Torre,
- Patricia Sunsundegui,
- Antonio González-Martín,
- Antonio González-Martín,
- Daniel Ajona,
- Daniel Ajona,
- Daniel Ajona,
- Daniel Ajona,
- Marcin Okrój,
- Felipe Prósper,
- Felipe Prósper,
- Felipe Prósper,
- Felipe Prósper,
- Ruben Pio,
- Ruben Pio,
- Ruben Pio,
- Ruben Pio,
- José Ramón Yuste,
- José Ramón Yuste,
- José Ramón Yuste,
- Beatriz Tavira,
- Beatriz Tavira,
- Beatriz Tavira
Affiliations
- Yaiza Senent
- Program in Solid Tumors, Translational Oncology Group, Cima-University of Navarra, Pamplona, Spain
- Yaiza Senent
- Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain
- Yaiza Senent
- Respiratory Tract Cancer Group, Navarra Institute for Health Research (IdISNA), Pamplona, Spain
- Susana Inogés
- Respiratory Tract Cancer Group, Navarra Institute for Health Research (IdISNA), Pamplona, Spain
- Susana Inogés
- Department of Immunology and Immunotherapy, Clinica Universidad de Navarra, Pamplona, Spain
- Susana Inogés
- Area of Cell Therapy and Department of Hematology, Clinica Universidad de Navarra, Pamplona, Spain
- Ascensión López-Díaz de Cerio
- Respiratory Tract Cancer Group, Navarra Institute for Health Research (IdISNA), Pamplona, Spain
- Ascensión López-Díaz de Cerio
- Department of Immunology and Immunotherapy, Clinica Universidad de Navarra, Pamplona, Spain
- Ascensión López-Díaz de Cerio
- Area of Cell Therapy and Department of Hematology, Clinica Universidad de Navarra, Pamplona, Spain
- Andres Blanco
- Department of Internal Medicine, Clinica Universidad de Navarra, Pamplona, Spain
- Arantxa Campo
- Pulmonary Department, Clinica Universidad de Navarra, Pamplona, Spain
- Francisco Carmona-Torre
- Respiratory Tract Cancer Group, Navarra Institute for Health Research (IdISNA), Pamplona, Spain
- Francisco Carmona-Torre
- Department of Internal Medicine, Clinica Universidad de Navarra, Pamplona, Spain
- Francisco Carmona-Torre
- Division of Infectious Diseases, Clinica Universidad de Navarra, Pamplona, Spain
- Patricia Sunsundegui
- Department of Internal Medicine, Clinica Universidad de Navarra, Pamplona, Spain
- Antonio González-Martín
- Program in Solid Tumors, Translational Oncology Group, Cima-University of Navarra, Pamplona, Spain
- Antonio González-Martín
- Department of Oncology, Clinica Universidad de Navarra, Madrid, Spain
- Daniel Ajona
- Program in Solid Tumors, Translational Oncology Group, Cima-University of Navarra, Pamplona, Spain
- Daniel Ajona
- Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain
- Daniel Ajona
- Respiratory Tract Cancer Group, Navarra Institute for Health Research (IdISNA), Pamplona, Spain
- Daniel Ajona
- 0Program in Respiratory Tract Tumors, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
- Marcin Okrój
- 1Department of Cell Biology and Immunology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, Gdańsk, Poland
- Felipe Prósper
- Respiratory Tract Cancer Group, Navarra Institute for Health Research (IdISNA), Pamplona, Spain
- Felipe Prósper
- Department of Immunology and Immunotherapy, Clinica Universidad de Navarra, Pamplona, Spain
- Felipe Prósper
- 0Program in Respiratory Tract Tumors, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
- Felipe Prósper
- 2Program of Regenerative Medicine, Cima-University of Navarra, Pamplona, Spain
- Ruben Pio
- Program in Solid Tumors, Translational Oncology Group, Cima-University of Navarra, Pamplona, Spain
- Ruben Pio
- Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain
- Ruben Pio
- Respiratory Tract Cancer Group, Navarra Institute for Health Research (IdISNA), Pamplona, Spain
- Ruben Pio
- 0Program in Respiratory Tract Tumors, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
- José Ramón Yuste
- Respiratory Tract Cancer Group, Navarra Institute for Health Research (IdISNA), Pamplona, Spain
- José Ramón Yuste
- Department of Internal Medicine, Clinica Universidad de Navarra, Pamplona, Spain
- José Ramón Yuste
- Division of Infectious Diseases, Clinica Universidad de Navarra, Pamplona, Spain
- Beatriz Tavira
- Program in Solid Tumors, Translational Oncology Group, Cima-University of Navarra, Pamplona, Spain
- Beatriz Tavira
- Respiratory Tract Cancer Group, Navarra Institute for Health Research (IdISNA), Pamplona, Spain
- Beatriz Tavira
- 3Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain
- DOI
- https://doi.org/10.3389/fimmu.2021.767376
- Journal volume & issue
-
Vol. 12
Abstract
Evidence supports a role of complement anaphylatoxin C5a in the pathophysiology of COVID-19. However, information about the evolution and impact of C5a levels after hospital discharge is lacking. We analyzed the association between circulating C5a levels and the clinical evolution of hospitalized patients infected with SARS-CoV-2. Serum C5a levels were determined in 32 hospitalized and 17 non-hospitalized patients from Clinica Universidad de Navarra. One hundred and eighty eight serial samples were collected during the hospitalization stay and up to three months during the follow-up. Median C5a levels were 27.71 ng/ml (25th to 75th percentile: 19.35-34.96) for samples collected during hospitalization, versus 16.76 ng/ml (12.90-25.08) for samples collected during the follow-up (p<0.001). There was a negative correlation between serum C5a levels and the number of days from symptom onset (p<0.001). C5a levels also correlated with a previously validated clinical risk score (p<0.001), and was associated with the severity of the disease (p<0.001). An overall reduction of C5a levels was observed after hospital discharge. However, elevated C5a levels persisted in those patients with high COVID-19 severity (i.e. those with a longest stay in the hospital), even after months from hospital discharge (p=0.020). Moreover, high C5a levels appeared to be associated with the presence of long-term respiratory symptoms (p=0.004). In conclusion, serum C5a levels remain high in severe cases of COVID-19, and are associated with the presence of respiratory symptoms after hospital discharge. These results may suggest a role for C5a in the long-term effects of COVID-19 infection.
Keywords